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Trabectedin and ifosfamide are among the few cytostatic agents active in advanced soft tissue sarcomas (STSs). Trabectedin is most
potent against so-called L-sarcomas (leiomyosarcoma and liposarcoma).(e survival gain and cost-eﬀectiveness of these agents in
a second-line setting were analysed in the setting of advanced STS after failure of anthracyclines. A prospective observational trial
had previously been performed to assess the use of trabectedin in a Dutch real-world setting. Data on ifosfamide monotherapy
were acquired from previous studies, and an indirect comparison of survival was made. A state-transition economic model was
constructed, in which patients could be in mutually exclusive states of being preprogression, postprogression, or deceased. (e
costs and quality-adjusted life years (QALYs) for both treatments were assessed from a Dutch health-care perspective. Separate
analyses for the group of L-sarcomas and non-L-sarcomas were performed. Trabectedin treatment resulted in a median
progression-free survival of 5.2months for L-sarcoma patients, 2.0months for non-L-sarcoma patients, and a median overall
survival of 11.8 and 6.0months, respectively. For L-sarcoma patients, trabectedin oﬀered an increase of 0.368 life years and 0.251
QALYs compared to ifosfamide and €20,082 in additional costs, for an incremental cost-eﬀectiveness ratio (ICER) of €80,000 per
QALY gained. In the non-L-sarcoma patients, trabectedin resulted in 0.413 less life years and 0.266 less QALYs, at the increased
cost of €4,698. (e diﬀerence in survival between drugs and the acquisition costs of trabectedin were the main inﬂuences in these
models. Trabectedin was shown to have antitumour eﬃcacy in advanced L-sarcoma. From a health economics perspective, the
costs per QALY gained compared to ifosfamide monotherapy that may be acceptable, considering what is currently regarded as
acceptable in the Netherlands.
1. Introduction
Soft tissue sarcomas (STSs) are a rare group of malignancies
arising from mesenchymal cells comprising one percent of
all adult malignancies. STSs in general are relatively in-
sensitive to chemotherapy compared to tumours of epithelial
origin. Some drugs, such as doxorubicin, have been found
active in a range of diﬀerent sarcoma subtypes, whereas
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others show only activity in speciﬁc subtypes, such as cri-
zotinib in the inﬂammatory myoﬁbroblastic tumour [1].
Trabectedin is a drug active in several subtypes, with most
notable eﬀect in leiomyosarcoma and liposarcoma. It has a
unique mechanism of action in binding to the minor groove
of DNA and also in inﬂuencing the tumour environment
[2, 3].
Trabectedin was approved for clinical use in Europe in
2007 for patients with advanced STS after failure to
anthracyclines and ifosfamide or for patients unsuited to
receive these agents. At this time, studies with a randomised
comparison with other treatment options were not available.
(erefore, before market authorization in the Netherlands
could be granted, a prospective observational trial was
designed, which aimed to analyse the use of trabectedin in
STS in a real-world setting.
(e original aim of this observational trial was to analyse
the use of trabectedin compared to best supportive care
(BSC) and derive an incremental cost-eﬀectiveness ratio
(ICER) for its use compared to BSC. All patients eligible for
trabectedin were also given the option of BSC, but only a few
patients opted for BSC, which made it impossible to draw
meaningful conclusions from this small number of patients.
Instead, as an alternative, a comparison with ifosfamide in
retrospective data was sought, as this drug is a treatment
option for patients with advanced STS after failure to
anthracyclines. Ifosfamide is an alkylating agent and
available since the 1980s for the treatment of STSs.
(erefore, this study aims to compare both survival and
cost-eﬀectiveness between trabectedin and ifosfamide in the
setting of second-line cytostatic treatment of STS in the
Netherlands.
2. Methods
2.1. Patient Selection. In order to facilitate the entry and
reimbursement of trabectedin in the Dutch health-care
system, a cost-eﬀectiveness analysis was designed to eval-
uate trabectedin and BSC usage patterns and outcomes in
advanced STS in a real-world setting, including data on
quality of life and associated utilities. (is prospective ob-
servational phase IV trial was to provide the Dutch health
authority (Zorginstituut Nederland) with suﬃcient data on
the eﬀectiveness and optimal use of trabectedin to ensure a
proper evaluation for permanent registry in the Regulation
Orphan Drugs.(is trial was named ET-D-010-10, with trial
registration number NCT01299506. (e RECIST 1.1 criteria
were used for response evaluation. Quality-of-life data were
scored using patient-reported EQ-5D questionnaires. Pa-
tients with all subtypes of STS were recruited in this trial if
they were eligible for trabectedin, after the failure of
anthracyclines and/or ifosfamide, or in case, these patients
were unsuited to receive these drugs. (e patients in this
observational trial were oﬀered treatment with trabectedin
or BSC, and the latter could consist of no systemic che-
motherapy or other systemic antitumour therapies. Some of
the included patients received trabectedin in a diﬀerent line
of therapy than second line, and those patients were not used
in the current analysis. All patients were adult and signed an
Institutional Review Board approved informed consent form
[4].
At the time of the ET-D-010-10 observational trial, no
study had yet directly compared the eﬃcacy of trabectedin to
BSC. Hence, the choice of treatment was with the patient and
local physician, as long as the patient was deemed ﬁt enough
to receive chemotherapy. It was intended to include 100
patients, of whom 80 would have received trabectedin and 20
would have chosen BSC. In reality, however, a larger portion
of patients wished to be treated with trabectedin (91%) than
predicted, and too few patients chose the BSC arm (total 9%:
6% only BSC and 3% received additional or other systemic
antitumour therapies). Despite an extension of the trial
duration, accrual of the BSC arm was insuﬃcient to be able
to perform a viable comparison of the collected data.
To account for the lack of a trial-generated comparator
group, it was decided to perform an indirect comparison of
the data in the trabectedin arm with data obtained from
previous studies. As appropriate data on patients on BSC
were not available, an agent active as second-line treatment
was sought. (ese data were obtained from two EORTC
clinical trials with ifosfamide in patients with advanced STS,
published by Nielsen et al. and van Oosterom et al., hereafter
termed “the EORTC trials” [5, 6]. (ese two trials used the
1979 WHO criteria for response evaluation. According to
the 2018 ESMO guideline on STS treatment, after doxoru-
bicin, patients may be treated with ifosfamide, if they did not
progress on it previously [1].(erefore, a second-line setting
was chosen for comparing the phase IV ET-D-010-10 data
on trabectedin with the EORTC data on ifosfamide.
(e eﬃcacy of ifosfamide diﬀers in STS subtypes to a
certain extent, but has not been shown to diﬀer as much
between subtypes as trabectedin does. Trabectedin has a
markedly better eﬃcacy in leiomyosarcoma and liposarcoma
subtypes, the so-called L-sarcomas. (is diﬀerence in eﬃ-
cacy between L-sarcomas and non-L-sarcomas has led to
clinical trials which speciﬁcally included patients with one of
these two subtypes [2]. Due to the prominence of the
L-sarcomas in trabectedin clinical research, it was decided to
split the study population into two subsets, consisting of
L-sarcomas and non-L-sarcomas.
Out of all patients included in the phase IV trial, 54
patients received trabectedin as second-line treatment. (e
remaining 39 patients received trabectedin as third or
higher line of treatment and were excluded from the cost-
eﬀectiveness analysis. (e drug was prescribed in the ac-
cepted regimen of 1.5mg/m2 once every 3 weeks during a
24-hour hospital admission. Due to dose reductions, the
average administered trabectedin dose was 1.3mg/m2.
From the ifosfamide trials, a total of 50 patients were
identiﬁed to ﬁt the criterion of second-line treatment. (e
ifosfamide dosage was 9 g/m2 given in 3 consecutive days
every 3 weeks (19 patients) [6], or 12 g/m2 as a 3-day
continuous infusion every 4 weeks (31 patients) [5], to-
gether with intravenous Mesna to prevent hemorrhagic
cystitis. For the cost-eﬀectiveness analysis, the regimen of
9 g/m2 was modelled, as it is current practice in the
Netherlands. Based on the EORTC trials, a dose intensity of
95% was implemented.
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2.2. Survival Analysis. (e duration of progression-free
survival (PFS) was taken as the time from the ﬁrst dose
of either study drug until disease progression. (e latter
could be based on radiology ﬁndings or in case of tra-
bectedin on clinical evaluation and cessation of treatment
due to it. Duration of overall survival (OS) was counted from
the day of the ﬁrst study drug dose until death by any cause.
To perform an indirect nonparametric analysis of survival,
the Kaplan–Meier method and the logrank test were used.
(e ECOG performance score was considered to be prog-
nostic for survival, more so than sex or age in patients who
require second-line chemotherapy for STS. An ECOG
performance score of 0 was classiﬁed as low and a score of 1
or 2 as high. A Cox regression analysis was used for mul-
tivariate tests, in which ECOG performance score and the
drug received were included into the analysis. Survival
probabilities at 3 and at 6months per treatment and group of
sarcomas were calculated based on observed progression-
free survival, and the number of treatment cycles was noted.
2.3. Cost-Eﬀectiveness Analysis. A state-transition model
was constructed to estimate healthcare costs and quality-
adjusted life years (QALY), separately for the L-sarcoma and
the non-L-sarcoma patients. In this model, patients were in a
mutually exclusive state of either preprogression survival,
postprogression survival (being overall survival (OS) minus
preprogression survival), or deceased. (e pre- and post-
progression average discounted life expectancies (DLEs)
were calculated for each treatment. Lifetime costs and
QALYs for treatment T, being either trabectedin or ifos-
famide, were calculated as follows:
costsT � CT + Cpreprogression × DLET,preprogression
+ Cpostprogression × DLET,postprogression,
QALYT � −UT + Upreprogression × DLET,preprogression
+ Upostprogression × DLET,postprogression,
(1)
where CT is the cost for treatment, such as drug acquisition
and administration, and also those due to adverse events and
UT is the QALY loss due to adverse events. (e Cpreprogression
and Cpostprogression denote the annual treatment-unrelated
costs before and after progression. Similarly, Upreprogression
and Upostprogression denote the utilities before and after
progression. Each of these model parameters is described in
more detail below. Subsequently, the incremental cost-
eﬀectiveness ratio (ICER) was calculated as follows:
ICER �
coststrabectedin − costsifosfamide
QALYtrabectedin −QALYifosfamide. (2)
Consistent with the Dutch guidelines [7], life years (LYs),
QALYs, and costs were discounted at 0%, 1.5%, and 4%,
respectively. A lifetime horizon was used, and costs are
reported in Euros at price level 2018. Other model com-
ponents are described below. Additional lines of antitumour
therapies had not been recorded in the EORTC or ET-D-
010-10 trial, and these were not assumed in the cost-
eﬀectiveness analysis.
2.3.1. Survival. PFS and OS data of trabectedin and ifos-
famide treatments were directly taken from the ET-D-010-
10 and EORTC trials, respectively. Table 1 details the
number of patients from each study, as well as baseline
characteristics. To estimate average survival times, para-
metric survival analyses were used, in which all patients were
pooled, regardless of treatment.(is facilitated extrapolating
survival beyond study follow-up and correcting for the
(nonsigniﬁcant) diﬀerence in the ECOG performance score
between the prospective trabectedin and retrospective
ifosfamide patients. Lognormal distributions were used,
based on the Akaike information criterion (data not shown,
considered alternative distributions were loglogistic, expo-
nential, gamma, Gompertz, and Weibull distributions).
Table 2 shows the estimated μ and σ for each treatment in
each group of sarcomas for PFS and OS, as well as the
associated average survival duration in months and years.
2.3.2. Utilities. Utility values represent the valuation of
health, on a scale anchored at 1 for perfect health and 0 for
health as poor as deceased.(e ET-D-010-10 trial could only
provide preprogression utility data, which was scored using
the EQ-5D and on average was 0.764. (erefore, EQ-5D
utility estimates for patients receiving second-line chemo-
therapy from the SABINE trial were used. In the SABINE
trial, the health-related quality of life was assessed in patients
with metastatic sarcoma from North America and Europe,
including patients from the Netherlands [8]. Converting the
UK tariﬀ to the Dutch tariﬀ resulted in the pre- and
postprogression utility score of 0.754 and 0.614, respectively.
As the preprogression utility in the SABINE trial was very
similar to the utility found in the ET-D-010-10 trial, the
usage of the SABINE utilities was considered appropriate.
Utilities were assumed equal for L-sarcoma and non-L-
sarcoma patients and equal for both trabectedin and ifos-
famide treatment groups, except for the disutility caused by
adverse events.
2.3.3. Health-Care Costs. Costs for trabectedin and ifosfa-
mide cycles included drug acquisition costs and drug ad-
ministration costs, as shown in Table 3. Drug administration
costs included the costs for hospitalization and blood tests
and imaging. (e majority of costs for trabectedin cycles
consisted of trabectedin acquisition costs, €4,238 out of€5,877 per cycle. For ifosfamide cycles, on the other hand,
the 5-day hospitalization formed the largest part of the costs,€2,470 out of €4,474 per cycle. A one-time treatment cost
was added to include the cost for insertion of a central
venous catheter (CVC), which was mandatory for all pa-
tients receiving trabectedin and amounted to €1,015.
Nontreatment-related monthly healthcare costs were esti-
mated for patients by extracting these data from the ET-D-
010-10 study.(ese costs were estimated separately from the
pre- and postprogression period and assumed equal for
L-sarcoma and non-L-sarcoma patients and equal for the
trabectedin and ifosfamide treatment groups. During pre-
progression survival, monthly costs were €284, and during
postprogression survival, this rose to €461, as shown in
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Table 4. Costs were taken from Dutch publicly available
sources. Prices were corrected for inﬂation to obtain 2018
levels.
2.3.4. Adverse Events. Adverse events were scored in the
EORTC and wider ET-D-010-10 trials, and the incidence
and duration of adverse events were taken directly from
these trials, as shown in Table 5. Adverse events were as-
sumed equal for L-sarcoma and non-L-sarcoma patients.
Disutility and costs of data per adverse event were taken
from the literature and converted to Dutch tariﬀs and 2018
price levels. In this indirect comparison, trabectedin resulted
in more frequent elevation of liver enzymes compared to
ifosfamide, whereas ifosfamide gave more neutropenia, with
its associated febrile neutropenia.(e total QALY loss due to
adverse events was 0.00153 for trabectedin and 0.00352 for
ifosfamide, with costs of €1,119 and €1,841, respectively.
2.3.5. Sensitivity Analyses. To assess the sensitivity of the
model for variations of key parameters, univariate sensitivity
analyses were performed and presented in a tornado dia-
gram.(e diﬀerence in PFS and OS between trabectedin and
ifosfamide was varied over the 95% conﬁdence interval (95%
CI) in the parametric survival analysis. (e other tested
variables were increased or decreased by 20%, which in-
cluded costs of trabectedin, costs of ifosfamide, costs of
Table 1: Baseline characteristics of study population.
Baseline characteristics of study population L-Sarcoma number (%) Non-L-sarcoma number (%)
Trabectedin Ifosfamide Trabectedin Ifosfamide
Age at ﬁrst dose Mean (SD) 55 (12) 54 (10) 57 (14) 45.3 (14)
Sex Female 16 (42.1) 9 (47.4) 9 (56.3) 19 (61.3)Male 22 (57.9) 10 (52.6) 7 (43.8) 12 (38.7)
ECOG PS 0 18 (47.4) 10 (52.6) 9 (56.3) 8 (25.8)1 + 2 20 (52.6) 9 (47.4) 7 (43.8) 23 (74.2)
Study size
ET-D-010-10 38 (100.0) — 16 (100.0) —
Nielsen et al. — 14 (73.7) — 17 (54.8)
Oosterom et al. — 5 (26.3) — 14 (45.2)
Drug received Trabectedin 38 (100.0) — 16 (100.0) —Ifosfamide — 19 (100.0) — 31 (100.0)
Disease status Local disease 10 (26.3) 1 (5.3) 2 (12.5) 9 (29.0)Metastatic disease 28 (73.7) 18 (94.7) 14 (87.5) 22 (71.0)
Tumour histology
Leiomyosarcoma 19 (50.0) 13 (68.4) — —
Liposarcoma 19 (50.0) 6 (31.6) — —
UPS — 6 (37.5) 4 (19.4)
Synovial sarcoma — 5 (31.3) 7 (22.6)
Neurogenic sarcoma — — 4 (12.9)
Hemangiosarcoma — — 3 (9.7)
Rhabdomyosarcoma — — 3 (9.7)
Others — 5 (31.3) 8 (25.8)
SD: standard deviation; ECOG-PS: ECOG performance score; UPS: undiﬀerentiated pleomorphic sarcoma.
Table 2: Progression-free survival rate age at 3 and at 6months, the mean and median number of treatment cycles received, the parametric
description of survival with the lognormal distribution, and average survival times. (e estimated average survival time with the lognormal
distribution is calculated by exp (μ+ σ2/2).
Progression-free survival L-Sarcoma Non-L-sarcoma
Trabectedin Ifosfamide Trabectedin Ifosfamide
PFS probability (%) At 3months 59.5 47.4 37.5 51.6At 6months 41.7 15.8 18.8 22.6
N treatment cycles Mean 6.1 3.8 3.8 3.4Median 6 4 3 3
Parametric analysis of survival
PFS μ 1.50 1.08 1.00 1.20σ 1.05 1.05 1.04 1.04
Average PFS In months 7.75 5.07 4.64 5.71In years 0.65 0.42 0.39 0.48
OS μ 2.42 2.15 1.77 2.21σ 1.00 1.00 0.94 0.94
Average OS In months 18.58 14.17 9.09 14.18In years 1.55 1.18 0.76 1.18
PFS: progression-free survival; OS: overall survival.
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hospitalization per day, utility preprogression, utility post-
progression, and body surface area.
3. Results
3.1. Patient Characteristics. A total of 54 patients received
trabectedin after doxorubicin in the phase IV trial from
December 2010 to April 2014, and a total 50 patients were
included from the EORTC trials published by Nielsen et al.
and van Oosterom et al. (e subsets of L-sarcoma and non-
L-sarcoma consisted of 57 and 47 patients, respectively, as
shown in Table 1.
3.2. SurvivalAnalysis. L-Sarcoma patients had a median PFS
of 5.2months on trabectedin, and 2.6months on ifosfamide,
as shown in Table 6. (e diﬀerence in PFS in this indirect
comparison showed a trend favouring trabectedin, but did
not reach statistical signiﬁcance with a p value of 0.074. In
the multivariate regression, the drug received continued to
show a trend with a hazard ratio (HR) of 0.60 (95% CI,
0.33–1.07) and p value of 0.086. (e median OS for
L-sarcoma patients on trabectedin was 11.8months, and on
ifosfamide 8.2months, also a nonsigniﬁcant diﬀerence (p
value, 0.184). For OS, high ECOG performance score at
baseline showed an association with reduced survival in both
univariate and multivariate tests, with a HR of 1.91 (95% CI,
1.06–3.45) and p value 0.032, in the multivariate analysis.
For non-L-sarcoma patients receiving trabectedin, the
PFS was 2.0months, and for patients who received ifosfa-
mide, PFS was 3.3months, p value 0.819. High ECOG
performance score was associated with a worse PFS in both
Table 3: Treatment-related costs of trabectedin and ifosfamide, for the average number of treatment cycles (see Table 2).
Treatment-related costs Trabectedin Ifosfamide
Unit Price Source Use Costs Use Costs
Trabectedin 1mg vial €1,956 [9] 2.17 €4,238 — —
Trabectedin 0.25mg vial €506 [9] 1.85 €938 — —
Ifosfamide 2mg vial €121 [9] — — 8.87 €1,070
Dexamethasone 20mg vial €9 [9] 1 €9 — —
Granisetron 1mg vial €4 [9] 2 €8 4 €16
Dexamethasone 8mg vial €3 [9] 1 €3 4 €11
Mesna 0.4mg vial €9 [9] — — 1 €718
Hospitalization per day €494 [7] 1 €494 5 €2,470
Full laboratory test €43 [10] 1 €43 1 €43
Haematological test €18 [10] 0.25 €5 0.25 €5
CT scan €157 [11] 0.25 €71 0.25 €71
MRI scan €264 [11] 0.25 €13 0.25 €13
Blood transfusion €224 [7] 0.25 €56 0.25 €56
Drug costs per cycle
Drug acquisition costs €5,175 €1,070
Drug administration costs €702 €3,403
Drug costs, total per cycle €5,877 €4,474
One-time treatment costs
CVC insertion €1,015 [11] 1 €1,015 0.30 €305
Total treatment costs
(i) L-Sarcoma €36,895 €17,081
(ii) Non-L-sarcoma €23,595 €15,601
Mesna: 2-mercaptoethanesulfonate sodium.
Table 4: Nontreatment-related costs per month during preprogression survival and postprogression survival.
Nontreatment-related costs per month Preprogression survival Postprogression survival
Unit Price Source Average use Cost Average use Cost
Hospitalization per day €494 [7] 0.21 €106 0.48 €236
Full laboratory test €43 [10] 1.02 €44 1.24 €54
Haematological test €18 [10] 0.16 €3 0.13 €2
CT scan €157 [11] 0.31 €49 0.37 €58
MRI scan €265 [11] 0.01 €2 0.00 €0
Blood transfusion €224 [7] 0.09 €20 0.00 €0
General practitioner visit €34 [7] 0.01 €0 0.03 €1
Medical oncologist visit €102 [7] 0.58 €59 1.08 €110
Nurse €34 [7] 0.01 €0 0.02 €1
Psychologist €82 [7] 0.01 €1 0.00 €0
Total costs per period €284 €461
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univariate test and multivariate test, with a HR of 2.43 (95%
CI, 1.16–5.07) and p value 0.018 in the latter test. Median OS
in this group was 6.0months for trabectedin and 8.9months
for ifosfamide treatment (p value, 0.903). High ECOG
performance score was associated with shorter duration of
OS, and in the multivariate test, a HR of 2.99 (95% CI,
1.44–6.20), p value 0.003.
Patients with an L-sarcoma had a PFS probability at
3months of 59.5%, and at 6months of 41.7% when receiving
trabectedin, as shown in Table 2. In this group, a mean of 6.1
and median of 6 treatment cycles were given. Patients who
had a non-L-sarcoma or who received ifosfamide had
shorter survival and received fewer cycles of chemotherapy.
3.3. Cost-Eﬀectiveness Analysis. (e results from the cost-
eﬀectiveness model are shown in Table 7. Results from the
parametric survival analysis were consistent with the
nonparametric survival analyses. For L-sarcoma patients,
trabectedin produced longer PFS and OS than ifosfamide
did. For non-L-sarcoma patients, ifosfamide treatment
produced longer PFS and OS than trabectedin.
For patients with L-sarcoma, the total discounted costs
were €44,879 for trabectedin and €24,797 for ifosfamide.
Costs for trabectedin acquisition were higher than for
ifosfamide (€31,597 vs. €4,113, respectively), but drug ad-
ministration costs were lower for trabectedin than ifosfa-
mide (€5,298 vs. €13,380, respectively). (e latter diﬀerence
was due to longer hospitalization needed for ifosfamide
cycles. (e nontreatment related monthly costs were higher
for trabectedin owing to longer survival compared to ifos-
famide (€6,866 vs. €5,464, respectively).(e costs for adverse
events were lower for trabectedin than for ifosfamide (€1,119
vs. €1,841, respectively). (ese treatments resulted in 1.524
and 1.169 LY gained, respectively, which gives an ICER of€56,000 per LY gained. QALYs were 1,025 for trabectedin
Table 6: Nonparametric analysis of survival for L-sarcoma and non-L-sarcoma patients, univariate Kaplan–Meier analysis with median
survival in months and logrank test, and multivariate Cox regression. (e univariate hazard ratio for age per year increase was 0.99 for all
tests.
Nonparametric survival L-Sarcoma Non-L-sarcoma
Univariate Kaplan–Meier Median PFS 95% CI p value Median PFS 95% CI p value
Progression-free survival
Age 0.96–1.02 0.395 0.97–1.01 0.460
Sex
(i) Female 3.19 0.00–6.62 0.621 2.89 1.76–4.03 0.931
(ii) Male 4.57 2.43–6.71 2.30 0.81–3.80
ECOG PS
(i) 0 3.68 1.08–6.28 0.602 3.22 0.00–6.45 0.022
(ii) 1 + 2 3.29 0.00–7.90 1.91 0.46–3.35
Drug received
(i) Trabectedin 5.19 3.31–7.07 0.074 2.04 1.52–2.55 0.819
(ii) Ifosfamide 2.63 0.43–4.83 3.25 2.33–4.18
Disease status
(i) Local 3.29 0.00–7.01 0.740 3.25 0.00–6.80 0.875
(ii) Metastatic 3.94 1.40–6.48 2.43 1.27–4.30
Multivariate Cox regression HR 95% CI p value HR 95% CI p value
(i) Drug received 0.60 0.33–1.07 0.086 1.35 0.67–2.74 0.403
(ii) ECOG PS 1.11 0.63–1.95 0.715 2.43 1.16–5.07 0.018
Univariate Kaplan–Meier Median OS 95% CI p value Median OS 95% CI p value
Overall survival
Age 0.96–1.02 0.498 0.97–1.01 0.273
Sex
(i) Female 8.35 2.66–14.0 0.071 9.17 5.63–12.7 0.796
(ii) Male 14.85 10.2–19.5 5.55 3.68–7.42
ECOG PS
(i) 0 13.41 7.57–19.2 0.033 13.77 7.72–19.8 0.008
(ii) 1 + 2 8.35 3.92–12.8 5.23 3.64–6.81
Drug received
(i) Trabectedin 11.80 7.78–15.8 0.184 5.98 0.70–11.3 0.903
(ii) Ifosfamide 8.22 0.00–21.2 8.94 5.97–11.9
Disease status
(i) Local 7.43 2.82–12.0 0.666 11.80 6.30–17.3 0.594
(ii) Metastatic 13.41 7.85–19.0 6.97 2.81–11.1
Multivariate Cox regression HR 95% CI p value HR 95% CI p value
(i) Drug received 0.66 0.37–1.18 0.162 1.73 0.85–3.50 0.128
(ii) ECOG PS 1.91 1.06–3.45 0.032 2.99 1.44–6.20 0.003
PFS: progression-free survival; OS: overall survival; 95% CI: 95% conﬁdence interval; ECOG PS: ECOG performance score; HR: hazard ratio.
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and 0.773 for ifosfamide, leading to an ICER of €80,000 per
QALY gained.
For patients with a non-L-sarcoma, ifosfamide domi-
nated trabectedin since costs were higher for trabectedin
than ifosfamide (€27,497 vs. €22,799, respectively), while
eﬀectiveness for trabectedin was worse in terms of LYs
(0.754 vs. 1.170, respectively) and in terms of QALYs (0.516
vs. 0.781, respectively).
3.4. Sensitivity Analyses. (e sensitivity analysis of L-sar-
coma showed the ICER to be most aﬀected by the diﬀerence
in survival between trabectedin and ifosfamide, as shown in
Figure 1. (is eﬀect was most prominent in OS. (e 95% CI
of the diﬀerence in OS for trabectedin and ifosfamide was−3.6 to 18.4months, and this meant an overlap of OS du-
ration. (is resulted in ICER ranging from €28,000 per
QALY gained in favour of trabectedin to ifosfamide being
dominant for OS. (e ICER across the 95% CI of PFS also
varied substantially, but QALYs remained in favour of
trabectedin, with the ICER ranging from €59,000 to €98,000
per QALY gained. Another clear inﬂuence on ICER varia-
tion was the cost of trabectedin, with the ICER ranging from€55,000 to €105,000.
As the base-case analysis showed ifosfamide to dominate
trabectedin in patients with non-L-sarcoma, a sensitivity
analysis for non-L-sarcoma was not performed.
4. Discussion
Trabectedin was shown to be an active drug in the second-
line treatment of L-sarcomas (either leiomyosarcoma or
liposarcoma). In this nonrandomised comparison, the
median survival of patients with L-sarcomas was
2.5months longer if they received trabectedin instead of
ifosfamide, not meeting the criterion for statistical sig-
niﬁcance (p � 0.074). In non-L-sarcoma, ifosfamide
resulted in longer survival, but the diﬀerence was not
signiﬁcant. (e cost-eﬀectiveness analysis of trabectedin
compared to ifosfamide showed an ICER of €80,000 per
QALY gained in case of L-sarcoma. For non-L-sarcoma,
ifosfamide dominated trabectedin as ifosfamide costs were
lower but survival and QALYs gained higher compared to
trabectedin treatment. Survival diﬀerences and trabectedin
acquisition costs had the strongest impact on the ICERs
found. Future changes in trabectedin pricing would alter
the ICER. However, given the status of trabectedin as
“orphan drug” due to the low incidence of malignancies
trabectedin is currently registered for, its price is not ex-
pected to change in the foreseeable future.
When this cost-eﬀectiveness analysis was designed, a
comparator group was sought that could provide for a
sensible comparison to second-line trabectedin. Ifosfamide
was chosen as this drug was widely tested in STS, and data
for second-line treatment were available at the EORTC. Due
to the adverse events and the long hospital admission per
treatment cycle, this drug has been used less extensively over
last decade, and alternatives are available. In terms of ex-
pected antitumour eﬀect, ifosfamide was still considered to
represent a realistic comparator group. Additionally, po-
tential alternative data sets would not match the patient
population of the trabectedin-treated patients.
(is cost-eﬀectiveness study was not a randomised
comparison, contrary to the designs of the original ifosfa-
mide studies. To reduce bias, survival was counted from the
moment of ﬁrst drug infusion, not the moment of trial
inclusion as in the original trials. (is was done to evade a
potential bias, wherein the duration of survival of either
ifosfamide or trabectedin would have been longer due to
eﬀects other than drug eﬀects. (erefore, the diﬀerence in
survival now reported is accurately reﬂecting survival fol-
lowing treatment.(e EORTC STBSG has used progression-
free rates (PFRs) as an indicator whether a drug is active as a
second-line agent in STS [22]. Agents considered active have
an estimated PFR at 3months of 39% and at 6months of
14%. For L-sarcoma, trabectedin showed, by this standard,
to be an active drug in this population with a PFR of 59% and
42%, respectively. For non-L-sarcoma, trabectedin was less
potent with a PFR at 3months just below the threshold at
37% and PFR at 6months at 19%. (e PFRs for ifosfamide
were above the EORTC STBSG number in both L-sarcoma
and non-L-sarcoma.
Table 7: Estimated average costs and eﬀectiveness, comparing trabectedin and ifosfamide in advanced L-sarcoma and non-L-sarcoma.
Cost-eﬀectiveness model
L-Sarcoma Non-L-sarcoma
Trabectedin Ifosfamide Diﬀerence Trabectedin Ifosfamide Diﬀerence
Costs (all discounted) €44,879 €24,797 €20,082 €27,497 €22,799 €4,698
(i) Drug acquisition €31,597 €4,113 €27,484 €19,407 €3,660 €15,747
(ii) Drug administration €5,298 €13,380 −€8,082 €3,646 €11,941 − €8,295
(iii) Nonrelated costs €6,866 €5,464 €1,402 €3,325 €5,357 − €2,032
(iv) Adverse events costs €1,119 €1,841 −€722 €1,119 €1,841 − €722
Eﬀectiveness
(i) QALYs, discounted 1.025 0.773 0.251 0.516 0.781 −0.265
(ii) Preprogression LYs, undiscounted 0.646 0.423 0.223 0.386 0.476 −0.090
(iii) Postprogression LYs, undiscounted 0.902 0.758 0.144 0.371 0.694 −0.323
Cost-eﬀectiveness ratios
(i) Costs per LY gained €56,000 Ifosfamide dominant
(ii) Costs per QALY gained €80,000 Ifosfamide dominant
QALYs: quality-adjusted life years; LY: life years.
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Several studies have previously investigated the cost-
eﬀectiveness of trabectedin in STS compared to other treat-
ments. In a 2011 study by Soini et al., trabectedin was
compared to ifosfamide [23]. Trabectedin data were taken
from a 2009 randomised trial comparing trabectedin treat-
ment regimen and ifosfamide data from the same studies by
van Oosterom andNielsen used in the current study [5, 6]. All
patients on trabectedin had an L-sarcoma, whereas sarcoma
subtypes were not clear for patients with ifosfamide.(e study
found an ICER per LY gained of € 31,590 and € 42,633–47,735
per QALY gained when prescribing trabectedin. (ese ICERs
are lower than in the current study, suggesting better tra-
bectedin cost-eﬀectiveness. (e most evident cause for this
diﬀerence is the higher survival beneﬁt due to ifosfamide in
the current study compared to Soini et al. (1.17 LY vs. 0.60 LY,
respectively), whereas there were higher costs of ifosfamide
treatment in Soini et al. (€13,053–14,286 vs. €7,568, re-
spectively). (e diﬀerence in survival gained due to ifosfa-
mide, even though these are taken from the same studies,
suggests a diﬀerence in patient selection between the cost-
eﬀectiveness studies.
A 2013 indirect comparison into the cost-eﬀectiveness of
doxorubicin-ifosfamide combination vs. trabectedin also
showed more QALYs gained at lower health-care costs for
doxorubicin-ifosfamide [24]. A pooled patient cohort from
four phase II studies of patients receiving trabectedin for
advanced STS was used in a 2015 study comparing the cost-
eﬀectiveness of trabectedin and the tyrosine kinase inhibitor
pazopanib [25]. (e HR calculated was 1.11 in favour of
pazopanib (with 95% CI of 0.94–1.31). Pazopanib treatment
costs were half the cost of trabectedin cycles. As pazopanib is
oral medication which is taken without the need for hospital
admissions, the majority of patients will prefer pazopanib for
that fact alone, regardless of costs. A study comparing
pazopanib to placebo in advanced STS patients resulted in an
ICER of €77,120 per QALY gained when taking pazopanib
treatment, illustrating the high costs of therapies aimed at
treating advanced STS [13].
Compared to the 2016 randomised phase III trial by
Demetri et al. comparing trabectedin vs. dacarbazine in
pretreated metastatic L-sarcoma patients, patients on tra-
bectedin in the current study in a real-life setting had a
higher median PFS (4.2 vs. 5.2months, respectively),
whereas OS was slightly lower (12.4months vs. 11.8months,
respectively) [26]. A possible explanation for the PFS dif-
ference is the blinded radiologic evaluation of imaging to
assess PFS in the randomised trial. (e eﬃcacy of tra-
bectedin vs. dacarbazine showed better PFS for trabectedin
but equal OS [26]. Unfortunately, this trial did not include
QALY assessments.
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Overall survival (95% CI)
Costs for trabectedin (±20%)
Body surface area (±20%)
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Costs for hospitalization (±20%)
Costs for ifosfamide (±20%)
Costs for preprogression (±20%)
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Costs for adverse events (±20%)
–20%/low end of 95% CI
+20%/high end of 95% CI
Figure 1: Tornado diagram representing the univariate sensitivity analysis for L-sarcoma, numbers abbreviated to thousands. All variables
other than survival were increased (light-shaded bars) or decreased (dark-shaded bars) by 20%. For progression-free survival and overall
survival, the 95% conﬁdence interval (95% CI) of the survival diﬀerence between trabectedin and ifosfamide was used (low end: light-shaded
bars; high end: dark-shaded bars). Note that the bar for the low end of the diﬀerence in OS does not stop and no number is given, as
ifosfamide dominated trabectedin at that point, with a negative ICER. OS: overall survival; PFS: progression-free survival.
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A study by Le Cesne ABJYC et al. presented at the 2018
ASCO meeting randomised pretreated advanced STS pa-
tients between trabectedin and BSC, giving the comparison
originally attempted for this cost-eﬀectiveness analysis [27].
In that trial, trabectedin showed better PFS than BSC for
L-sarcomas (5.3 vs. 1.4months, respectively), but not for
non-L-sarcomas (1.8 vs. 1.5months, respectively). OS did
not diﬀer, and this was deemed due to per-protocol
crossover to trabectedin after progressive disease on BSC.
(is trial demonstrates the eﬃcacy of trabectedin for
L-sarcomas compared to BSC. (e eﬃcacy of trabectedin
within the group of L-sarcomas also varies, and it oﬀers the
largest beneﬁt in patients with myxoid liposarcoma [28].(e
actual size of the antitumour eﬀect in myxoid liposarcoma is
blunted in clinical trials as other liposarcoma subtypes, in
which trabectedin is less active, and are included in the same
trials. (e number of patients in this cost-eﬀectiveness
analysis was too small to detect any diﬀerences between
leiomyosarcomas vs. liposarcomas or myxoid liposarcomas
vs. other liposarcoma subtypes.
(is cost-eﬀectiveness analysis has several limitations,
especially since it was not possible to perform the study
originally set out to do.(e number of included patients was
constrained by the number of eligible patients in the ET-D-
010-10 and EORTC trials. (e criteria for response evalu-
ation were slightly diﬀerent, but this was considered not to
have an impact on the study’s conclusion. (e non-
randomised nature of the comparison may have introduced
bias, especially since the sensitivity analysis showed that the
estimated survival diﬀerence was the most inﬂuential var-
iable in the analysis. (e correction for ECOG performance
score was enacted to reduce this potential bias. Nevertheless,
the p values that are reported in the survival analysis dis-
regard the nonrandomized nature of the data.
(e use of data on patients treated with ifosfamide did
provide a sensible alternative, but those patients were treated
some twenty years before the patients who received tra-
bectedin. In those years, experience with safely adminis-
tering ifosfamide has increased, probably leading to lower
adverse event rates than those used in the current study.(is
may constitute a bias in favour of trabectedin in the study.
Other possible explanations for the diﬀerence in survival
include additional treatment options developed since the
ifosfamide trials were performed and advancements in
supportive and palliative care.
(is study was performed for a Dutch health-care setting
with chemotherapy given during hospital admissions. Ad-
ministrating trabectedin in an outpatient setting using
ambulatory pump is also possible [29]. (is method of
administration would be less costly and will aﬀect the ICER
in favour of trabectedin therapy. However, this method is
currently not standard in the Netherlands. Obviously, the
prices of health-care items will diﬀer in other countries, and
the ICER may be diﬀerent as a result.
5. Conclusions
Trabectedin was shown to oﬀer a nonsigniﬁcant survival
gain compared to ifosfamide for L-sarcoma, and this results
in an estimated ICER of €80,000. (is ICER is at the top end
of what is generally considered acceptable in the Netherlands
[30]. As there is a clinically unmet need for antitumour
agents in the group of rare malignancies, this threshold may
not be the most relevant factor in the decision to continue to
prescribe trabectedin to these patients. For non-L-sarcoma,
ifosfamide treatment dominated trabectedin.
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